A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)

Inclusion Criteria: * Hospitalized male or female subjects of ≥ 18 years of age at time of Screening who are being treated in the intensive care unit (ICU) for COVID-19 for not longer than 48 hours or for whom a decision has been made that COVID-19 disease severity warrants ICU admission. * Subject (or a legal representative or a nearest relative or a relative by marriage, as appropriate) provides informed consent (ICF) prior to initiation of any study procedures. * Has laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by qualitative Polymerase Chain Reaction (PCR) (reverse transcriptase \[RT\]-PCR), or other commercial or public health assay in any specimen during the current hospital admission prior to randomization. * Illness (symptoms) of any duration, and the following: 1. Radiographic infiltrates by imaging (chest x-ray, computerized tomography \[CT\] scan, etc.), and 2. Requiring mechanical ventilation and/or supplemental oxygen * Subjects with no limitation of therapeutic effort (decision on the status and future of the subject). * Female subjects of child-bearing potential must have a negative test for pregnancy blood or urine human chorionic gonadotropin (HCG)-based assay at Screening/Baseline Visit. Exclusion Criteria: * Clinical evidence of any significant acute or chronic disease that, in the opinion of the investigator, may place the subject at undue medical risk. * The subject has had a known serious anaphylactic reaction to blood, any blood-derived or plasma product or methylene blue. * A medical condition in which the infusion of additional fluid is contraindicated. * Shock unresponsive to fluid challenge and/or multiple vasopressors and accompanied by multiorgan failure considered by the Principal Investigator not able to be reversed.